264 results found

On October 10, 2024, the National Medical Products Administration in China released the Draft Rule on Rewarding Internal Whistleblowers for Reporting...

The medical aesthetics industry in China is experiencing a transformative phase, establishing itself as a leading global market segment...

Due to the coronavirus outbreak in China, official deadlines are automatically extended to Feburary 3, 2020 (Beijing time) and may be subject to further postponement.

On 22 January 2013, the PRC Ministry of Health issued the revised Good Supply Practice for Pharmaceutical Distribution, which will take effect 1 June 2013.

The Guidelines also require that the production date and use by period of the health food be clearly marked on the sales package, along with the producer's service hotline.

How the Opinions would be implemented is unclear and remains to be seen.

Some pioneering industrial players have already made movements in this regard.

On 19 September 2012, SFDA released the Rules on Imposing Administrative Penalties for Drugs and Medical Equipment.

Bio-Thera Solutions secures NMPA approval for BAT2306, China's first secukinumab biosimilar, while Biocon expands commercialization rights for its ustekinumab biosimilar YESINTEK across nine additional global markets. These developments mark significant milestones in the biosimilar landscape for autoimmune disease treatments.

The media controversy surrounding China's coronavirus COVID-19 detection app, the "close contact detector," has highlighted a common misapprehension

On September 28, 2013, China’s State Council published a plan titled Opinions on Promoting the Development of the Healthcare Services Industry, which outlines policy initiatives and development goals for China’s healthcare services industry to achieve by 2020 (the "Plan").

CCTV has reported that in order to achieve long-term profits, many milk companies had bribed doctors and nurses.

On January 31, 2020, the World Health Organization declared the outbreak of the novel coronavirus (2019-nCov),...

On October 21, 2024, the China National Medical Products Administration (NMPA) released a pilot plan that allows non-end-to-end manufacturing of biologics. The NMPA has a longstanding position to require an end-to-end...

On December 30, 2024, China's State Council published a series of policy incentives in Circular No. 53 to stimulate the transformation of the country's life sciences industry.

On February 7, 2014, the China Food and Drug Administration promulgated a notice titled "The Fast Track Approval Process for Innovative Medical Device (Tentative)", effective as of March 1, 2014.

In 2010,we witnessed an increasing number of enforcement actions taken by the local Administrations for Industry and Commerce ("AIC") in China against sales and promotional activities undertaken by healthcare companies, alleging commercial bribery.